COG AAML1522 /Celgene CC -5013-AML-002: a phase 2, multicenter, single-arm, open-label study to evaluate the activity, safety and pharmacokinetics of Lenalidomide (Revlimid®) in pediatric subjects from 1 to less than or equal to 18 years of age with relapsed or refractory acute myeloid leukemia,
Role: Investigator,
Children Oncology Group,
(01/2017 - 01/2018)
Status: Completed
COG-ACCL1131: A phase III open-label trial of caspofungin vs. azole prophylaxis for patients at high-risk for invasive fungal infections (IFI) following allogeneic hematopoietic cell transplantation (HCT),
Role: Investigator,
Children Oncology Group,
(04/2016 - 04/2017)
Status: Completed
NCI - Special exception protocol for chimeric MOAB 14:18 (IND #4308, NSC 623408) pediatric patients,
Role: Investigator,
National Cancer Institute/NIH/DHHS,
(09/2014 - 09/2015)
Status: Completed
COG-ANBL 12P1: pilot study using myeloblative Busulfan/Melphalan (BuMel) consolidation following induction chemotherapy for patients with newly diagnosed high-risk neuroblastoma,
Role: Investigator,
Children Oncology Group,
(06/2014 - 06/2015)
Status: Completed
For Profit Organization
Pfizer FRAG-A001-201 (A6301094): A three month prospective open label study of therapy with Fragmin® ( Dalteparin sodium injection) in children with venous thromboembolism with or without malignancies,
Role: Investigator,
Pfizer Inc., U.S. Pharmaceuticals Group,
(05/2017 - 05/2018)
Status: Completed
Internal
Tumor cell bank,
Role: Investigator,
LLU Dept. of Pediatrics,
(04/2016 - 04/2017)
Status: Completed